The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Official Title: A Phase I Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
Study ID: NCT02381886
Brief Summary: A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States
Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States
Uni of TX MD Anderson Cancer Cntr ., Houston, Texas, United States
Novartis Investigative Site, Melbourne, Victoria, Australia
Novartis Investigative Site, Parkville, Victoria, Australia
Novartis Investigative Site, Leuven, , Belgium
Novartis Investigative Site, Toronto, Ontario, Canada
Novartis Investigative Site, Heidelberg, , Germany
Novartis Investigative Site, Jena, , Germany
Novartis Investigative Site, Koeln, , Germany
ErasmusMC Cancer lnstitute, Neuro-Oncology, Rm G3-55, Rotterdam, , Netherlands
Novartis Investigative Site, Singapore, , Singapore
Novartis Investigative Site, Barcelona, Catalunya, Spain
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR